BioWorld

May 5, 2008

Discovery Labs Falls on Third Approvable Letter for Surfaxin

Discovery Laboratories Inc. received yet another approvable letter from the FDA for Surfaxin use in premature infants with respiratory distress syndrome, causing shares to fall more than 47 percent Friday. (BioWorld Today) Read More

Critical Therapeutics Investors Balk Over Cornerstone Merger

Study Links Gene to High Blood Sugar, Not to Type II Diabetes

Panel Supports Approval of Cinryze in Preventing in HAE

Congress Debates User Fees for Foreign Drug Inspections

Earnings Roundup

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 5, 2026.

ASCO 2026: A revolution in pancreatic cancer

BioWorld

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

BioWorld

Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...

Janssen Pharmaceutica reports new TMEM175 activators

BioWorld Science

Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...